PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
-1.08
Negative D/E while TRAW shows 0.00. Joel Greenblatt would look for hidden assets and restructuring catalysts.
-6.56
Net cash position while TRAW shows net debt of 10.47. Joel Greenblatt would examine if this balance sheet advantage creates strategic opportunities.
-32.85
Negative coverage while TRAW shows 0.00. Joel Greenblatt would look for operating improvements and turnaround potential.
1.75
Current ratio 75-90% of TRAW's 2.09. Bruce Berkowitz would look for working capital optimization opportunities.
No Data
No Data available this quarter, please select a different quarter.